Spotlight On... Pfizer joins Human Vaccines Project; PATH to open 'Center for Vaccine Innovation and Access' with $11M Gates Foundation grant; Cadila shares suffer on WHO plant inspection report; and more…

FDA

Pfizer ($PFE) enlisted in the Human Vaccines Project, joining an influential group of peers and research institutions setting out to "decode the human immune system." Founded at the International AIDS Vaccine Institute, the Human Vaccines Project so far has participation from a broad range of pharma partners and academic institutions, hoping that knowledge gained through the partnership will help in the development of vaccines against infectious diseases, cancer, flu, dengue and other targets. In addition to Pfizer, participants so far are Regeneron ($REGN), GlaxoSmithKline ($GSK), AstraZeneca's ($AZN) MedImmune, Sanofi Pasteur, Janssen, among others. Release

> Seattle-based nonprofit PATH plans to open a "Center for Vaccine Innovation and Access," with initial funding in the amount of $11 million coming from the Bill & Melinda Gates Foundation, according to reports. Release | More

> WHO regulators noted "several major deviations" at a Cadila Healthcare vaccine plant in India following a recent inspection, sending the company's shares downward. Report

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

> Soligenix netted $660,000 in NIAID funding to advance regulatory interactions on its heat stable ricin vaccine. Release

> Hyderabad-based Biological E received a Rs895 crore ($134 million) order from the country's health ministry to provide its 5-in-1 liquid pentavalent vaccine for the universal vaccination program. Report

Read more on

Suggested Articles

Amid the COVID-19 pandemic, many teams of researchers are working on potential vaccines. We asked experts to assess progress—and point out challenges.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.